Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales

Abstract Objectives To evaluate the cost-effectiveness of eltrombopag compared with romiplostim to be used in the treatment of chronic immune thrombocytopenia in patients in England and Wales who are splenectomized or ineligible for splenectomy and are refractory to other treatments. Methods A Marko...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2016-07, Vol.19 (5), p.614-622
Hauptverfasser:	Allen, Rachel, PhD, Bryden, Peter, MSc, Grotzinger, Kelly M., PhD, Stapelkamp, Ceilidh, MPH, Woods, Bethan, BA, MSc
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzoates - economics Benzoates - therapeutic use Chronic Disease chronic immune thrombocytopenia Cost-Benefit Analysis cost-effectiveness eltrombopag England Humans Hydrazines - economics Hydrazines - therapeutic use indirect treatment comparison Internal Medicine Markov Chains Pyrazoles - economics Pyrazoles - therapeutic use Receptors, Fc - therapeutic use Recombinant Fusion Proteins - economics Recombinant Fusion Proteins - therapeutic use romiplostim State Medicine Thrombocytopenia - drug therapy Thrombopoietin - economics Thrombopoietin - therapeutic use thrombopoietin receptor agonist Wales
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!